Patterns of proton pump inhibitor use in clinical practice

被引:63
作者
Barrison, AF
Jarboe, LA
Weinberg, BM
Nimmagadda, K
Sullivan, LM
Wolfe, MM
机构
[1] Boston Med Ctr, Gastroenterol Sect, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Gastroenterol Sect, Boston, MA 02215 USA
[3] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA
关键词
D O I
10.1016/S0002-9343(01)00901-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Little is known about differences between gastroenterologists and primary care physicians in their patterns of prescribing proton pump inhibitors. SUBJECTS AND METHODS: A survey of practicing primary care physicians from the American Board of Medical Specialties and practicing gastroenterologists from the American Gastroenterological Association was conducted by facsimile. The survey instrument consisted of 13 questions about pharmacokinetics and administration of proton pump inhibitors. RESULTS: The overall response rate was 15% (491 of 3273), and 80% (395 of 491) of respondents were nontrainee gastroenterologists or primary care physicians. Approximately 90% (n = 355) of eligible respondents correctly identified proton pump inhibitors as inhibitors of H+,K+-adenosinetriphosphatase. Proton pump inhibitors were prescribed by 80% (n = 314) of each group for reflux esophagitis, They were prescribed by 67% (122 of 182) of gastroenterologists and 27% (58 of 213) of primary care physicians to prevent ulcers induced by nonsteroidal anti-inflammatory drugs (P <0.001). And they were prescribed by 40% (n = 73) of gastroenterologists and 16% (n = 34) of primary care physicians for uncomplicated heartburn (P <0.001). Proton pump inhibitors were prescribed before a meal by 95% (n = 173) of gastroenterologists and 33% (n = 70) of primary care physicians (P <0.001). Nearly 99% (n = 391) of respondents agreed that proton pump inhibitors were safe, but only 15% (n = 59) thought they should be available without prescription. CONCLUSION: Our survey suggests that the use of proton pump inhibitors differs between gastroenterologists and primary care physicians. Furthermore, although most physicians believe that proton pump inhibitors are safe, few believe that they should be available without a prescription. (C) 2001 by Excerpta Medica, Inc.
引用
收藏
页码:469 / 473
页数:5
相关论文
共 25 条
[1]  
BARDHAN KD, 1995, ALIMENT PHARM THERAP, V9, P145
[2]   OMEPRAZOLE - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN PEPTIC-ULCER DISEASE AND ZOLLINGER-ELLISON SYNDROME [J].
CLISSOLD, SP ;
CAMPOLIRICHARDS, DM .
DRUGS, 1986, 32 (01) :15-47
[3]   INFLUENCE OF THE STIMULATION STATE OF THE PARIETAL-CELLS ON THE INHIBITORY EFFECT OF OMEPRAZOLE ON GASTRIC-ACID SECRETION IN DOGS [J].
DEGRAEF, J ;
WOUSSENCOLLE, MC .
GASTROENTEROLOGY, 1986, 91 (02) :333-337
[4]  
Dobrilla G, 1993, Clin Ther, V15 Suppl B, P2
[5]   TOTAL 24-HOUR GASTRIC-ACID SECRETION IN PATIENTS WITH DUODENAL-ULCER - COMPARISON WITH NORMAL SUBJECTS AND EFFECTS OF CIMETIDINE AND PARIETAL-CELL VAGOTOMY [J].
FELDMAN, M ;
RICHARDSON, CT .
GASTROENTEROLOGY, 1986, 90 (03) :540-544
[6]   OMEPRAZOLE - OVERVIEW AND OPINION [J].
HOLT, S ;
HOWDEN, CW .
DIGESTIVE DISEASES AND SCIENCES, 1991, 36 (04) :385-393
[7]  
HUBER R, 1995, ALIMENT PHARM THERAP, V9, P363
[8]  
IM WB, 1985, J BIOL CHEM, V260, P9452
[9]  
*IMS HLTH INC, 2000, NAT PRESCR AUD
[10]  
Katz PO, 1998, ALIMENT PHARM THER, V12, P1231